PTC Therapeutics, Inc. (NASDAQ:PTCT) announced a corporate update and reported its financial results for the fourth quarter and full-year ended December 31, 2013. In April 2013, PTC Therapeutics, Inc. (NASDAQ:PTCT) initiated the confirmatory Phase 3 ACT DMD (Ataluren Confirmatory Trial in DMD) clinical trial evaluating ataluren as a potential treatment for patients with nonsense mutation Duchenne muscular dystrophy (nmDMD). PTC Therapeutics, Inc. (NASDAQ:PTCT) stock performance … Continue reading Biotech Volatile Stocks: PTC Therapeutics (NASDAQ:PTCT), Agios Pharmaceuticals Inc (NASDAQ:AGIO), BioCryst Pharmaceuticals (NASDAQ:BCRX), TG Therapeutics (NASDAQ:TGTX)